Skip to main content
. 2019 Oct 14;10(10):784. doi: 10.1038/s41419-019-2023-1

Table 2.

miR-3163 expression and clinical outcome of sorafenib treatment

miR-3163 mRNA expression P
Low (n = 26) High (n = 26)
TTP 9.0 11.0 0.023
7.2–10.2 (M) 9.3–13.1 (M)
OS 11.0 16.0 0.012
8.0–14.0 (M) 10.4–21.6 (M)
Overall response rate (PR) 1 (3.84%) 3 (11.54%)
Disease control rate (PR + SD) 2 (7.69%) 12 (46.15%)

CR complete remission, M months, OS overall survival, PR partial remission, SD stable of disease, TTP time to progress